Kinderlehrer Daniel A
Private Practice, Denver, CO, USA.
Neuropsychiatr Dis Treat. 2025 Jan 29;21:141-155. doi: 10.2147/NDT.S500337. eCollection 2025.
The incidence of mental health disorders is increasing worldwide. While there are multiple factors contributing to this problem, neuroinflammation underlies a significant subset of psychiatric conditions, particularly major depressive and anxiety disorders. Anti-inflammatory interventions have demonstrated benefit in these conditions. Psilocin, the active ingredient of mushrooms in the genus, is both a potent serotonin agonist and anti-inflammatory agent, increases neuroplasticity, and decreases overactivity in the default mode network. Studies using hallucinogenic doses of psilocin under the supervision of a therapist/guide have consistently demonstrated benefits to individuals with depression and end-of-life anxiety. Microdosing psilocybin in sub-hallucinogenic doses has also demonstrated benefit in mood disorders, and may offer a safe, less expensive, and more available alternative to full doses of psilocybin for mood disorders, as well as for other medical conditions in which inflammation is the principal pathophysiology.
全球范围内精神健康障碍的发病率正在上升。虽然导致这一问题的因素众多，但神经炎症是相当一部分精神疾病的基础，尤其是重度抑郁和焦虑症。抗炎干预措施已在这些病症中显示出益处。裸盖菇素是该属蘑菇中的活性成分，它既是一种强效血清素激动剂，也是一种抗炎剂，可增强神经可塑性，并降低默认模式网络的过度活动。在治疗师/指导者的监督下使用致幻剂量裸盖菇素的研究一直表明，这对患有抑郁症和临终焦虑症的个体有益。以亚致幻剂量微剂量服用裸盖菇素也已在情绪障碍中显示出益处，并且对于情绪障碍以及炎症是主要病理生理学的其他病症而言，微剂量服用裸盖菇素可能提供一种安全、成本更低且更容易获得的替代全剂量裸盖菇素的方法。
